Plasminogen activator inhibitor-1 and haemostasis in obesity

Proceedings of the Nutrition Society

Volumn 60, Issue 3, 2001, Pages 341-347

  Mutch, N J ^a   Wilson, H M ^a   Booth, N A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cardiovascular disease; Insulin resistance; Obesity; PAI 1; Thrombosis

Indexed keywords

ANGIOTENSIN; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; GENE EXPRESSION; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; MOUSE; NONHUMAN; OBESITY; RAT; THROMBOGENESIS; THROMBOSIS;

ANIMALIA;

EID: 0034880542     PISSN: 00296651     EISSN: None     Source Type: Journal    
DOI: 10.1079/PNS200199     Document Type: Conference Paper

References (81)

1. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma
2. Cross talk between adipocytes and their precursors: Relationships with adipose tissue development and blood pressure
3. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity
4. Relation between plasma PAI activity and adipsin levels
5. Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease
6. Plasminogen activator inhibitors: Hormonally regulated serpins
7. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line HepG2: Metformin inhibits the stimulating effect of insulin
8. Studies on the fibrinolytic enzyme system in obesity
9. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes
10. Fibrinolysis and thrombosis
11. Stimulation of tissue-type plasminogen activator in vivo by infusion of bradykinin
12. Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects
13. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice
14. Atherosclerotic lesions: Possible interactive involvement of intima, adventitia and associated adipose tissue
15. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men
16. Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-α?
17. Purification and characterization of a plasminogen activator inhibitor I binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
18. Development of venous occlusions in mice transgenic for plasminogen activator inhibitor 1 gene
19. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
20. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals
21. Complete deficiency of plasminogen activator inhibitor type-1 due to a frameshift mutation
22. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity
23. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells
24. Fat distribution and hemostatic measures in obese children
25. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults
26. Angiotensin converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon injured rat aorta
27. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance
28. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
29. Plasminogen activator inhibitor 1 and atherothrombosis
30. PAI-1, obesity, insulin resistance and risk of cardiovascular events
31. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
32. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II
33. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1)
34. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss
35. Plasminogen activator inhibitor-1: Biosynthesis and messenger RNA level are increased by insulin in cultured human hepatocytes
36. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states
37. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
38. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
39. Regulation of PAI-1 gene expression
40. The fat mouse - A powerful genetic model to study hemostatic gene expression in obesity/NIDDM
41. Elaboration of type-1 plasminogen activator inhibitor from adipocytes - A potential pathogenetic link between obesity and cardiovascular disease
42. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
43. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects
44. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women
45. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
46. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity
47. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo
48. Angiotensin II induces the secretion of PAI-1 and a tissue metalloproteinase inhibitor related protein from rat brain astrocytes
49. Diabetes mellitus induces decreased plasma fibrinolytic activity and increased tissue synthesis of plasminogen activator inhibitor-1 (PAI-1) in the rat
50. Studies of the mechanism of inhibition of insulin signaling by tumor necrosis factor-alpha
51. The amount of plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility
52. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity
53. Role of insulin resistance in human disease
54. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
55. Proteins of the fibrinolytic system in human thrombi
56. Inhibitors of fibrinolysis are elevated in the atherosclerotic plaque
57. Obesity
58. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice
59. The fat mouse: A powerful genetic model to study elevated plasminogen activator inhibitor 1 in Obesity/NIDDM
60. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes
61. Tissue factor gene expression in the adipose tissues of obese mice
62. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
63. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo - Induction by tumor necrosis factor-alpha and lipopolysaccharide
64. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice
65. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β
66. Evidence for a local renin angiotensin system in primary cultured human preadipocytes
67. Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type 1 - Implications for vascular disease in hyperinsulinemic states
68. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
69. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
70. Plasminogen activator inhibitor (PAI-1): Distribution in human tissues
71. Fibrin deposition and fibrin degradation products in atherosclerotic plaques
72. Adipogenesis and obesity: Rounding out the big picture
73. Diet-induced changes in glucose and triglycerides are associated with changes in plasminogen-activator inhibitor levels
74. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss
75. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
76. Fat distribution and plasminogen activator inhibitor activity in non-diabetic obese women
77. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease
78. Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells
79. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo
80. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
81. The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity